Tacere Therapeutics develops human therapeutics based on RNA interference (RNAi) and ddRNAi gene-silencing technology from Benitec Biopharma. Using this approach, the drugs we create promise long term treatment or cure with a single dose.
We target human diseases for which there is currently no effective treatment. Our pipeline includes drugs for Hepatitis C and Age-Related Macular Degeneration.
Tacere Therapeutics is a Benitec Biopharma company.
Learn how our biological drugs target and silence genes, safely with lasting effect.
More 
Read how our Hepatitis C drug, TT-034, is poised for clinical trial in 2013.
More
17 April, 2013
HCV clinical trial application submitted to RAC
16 April, 2013
UCSD selected as site for HCV Phase I/II Trials
15 April, 2013
Benitec licensee secures orphan drug status
